Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health continuous glucose monitoring Coverage…
    Ask Trek AI about this page
    ModifiedModa HealthPolicy N/A

    Continuous Glucose Monitoring (CGM)

    Customize your policy alerts

    Sign up for all Moda Health policy alerts

    Know when Moda Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Moda Health coverage, prior authorization information, and clinical criteria for short-term diagnostic and long-term therapeutic use of FDA‑approved continuous glucose monitoring systems for members with diabetes.

    Policy Summary
    PayerModa Health
    PolicyContinuous Glucose Monitoring (CGM)
    Policy CodePolicy N/A
    Change TypeOperational update: implantable CGM criteria added
    Effective DateJun 1, 2026
    Last ReviewMay 27, 2026
    Next Review DateMay 27, 2026
    Key ActionInclude clinical documentation (progress notes, device training, recent HbA1c, glucose logs) with prior authorization requests for CGM.
    SourceLink
    POLICY UPDATE CHANGES

    Added requirements for implantable CGM and its continued usage and removed age limits.

    Updated CGM description and grammar for long-term therapeutic use; removed age limits.

    72 hrs–1 wkdiagnostic CGM duration covered
    >1 weektherapeutic CGM duration covered
    18+implantable CGM minimum age
    varies by device

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    sensor wear durations
    CPT/HCPCSbilling codes listed
    2026-06-01effective date

    Coverage Criteria for Continuous Glucose Monitoring (CGM)

    Short-term (diagnostic) CGM coverage

    Covered when ANY of the following diagnostic criteria are met for short-term use (72 hours to one week):

    Short-term diagnostic indications: Hypoglycemia unawareness; wide fluctuations of blood glucose levels despite documented blood glucose testing ≥4 times/day and insulin administration ≥3 times/day; unexplained frequent hypoglycemic episodes while on insulin therapy; repeated hypoglycemia (<50 mg/dL) or hyperglycemia (>150 mg/dL) at the same time each day; suspected postprandial hyperglycemia; recurrent diabetic ketoacidosis; prior to insulin pump initiation to determine basal insulin levels.duration 72 hours to 1 week

    Short-term (diagnostic) CGM use per Moda Health criteria.

    Long-term (therapeutic) CGM coverage

    Covered when ONE of the following is met (for members with Type I diabetes OR Type II diabetes who meet one of the following):

    Long-term therapeutic indications: Member has a diagnosis of Type I diabetes mellitus; OR member has a diagnosis of Type II diabetes mellitus AND one of the following: use of an intensive insulin regimen (multiple daily insulin injections or an insulin pump) and is not meeting daily glycemic targets; history of problematic hypoglycemia including hypoglycemia unawareness; documented wide fluctuations in blood glucose levels despite adherence to prescribed therapy; recurrent hypoglycemia or hyperglycemia that interferes with daily functioning or safe diabetes management.duration >1 week

    Long-term (therapeutic) CGM use for FDA-approved devices and related supplies.

    Continuation (ongoing) coverage criteria

    Continuation of CGM coverage requires ALL of the following:

    Continuation criteria: Ongoing clinical benefit demonstrated by improved glycemic control, stabilization of glucose patterns, or decrease in frequency or severity of hypoglycemic events; adherence to the member's CGM regimen and diabetes treatment plan; clinical assessment by the treatment provider at least every 6 months; documentation from the ordering provider that the member is compliant when requesting ongoing diabetic supplies.clinical assessment every 6 months

    Applies to continuation of long-term CGM coverage and supplies.

    Implantable CGM coverage

    Implantable CGM systems (e.g., Eversense) may be considered medically necessary when ALL of the following are met:

    Implantable CGM requirements: Member is 18 years of age or older; member meets the criteria for long-term therapeutic CGM; documentation of clinical need for an implantable system (for example, inability to tolerate or adhere to transcutaneous sensor wear, recurrent adhesion or skin intolerance, or device handling problems).age >=18 years

    Device must be FDA-approved and clinical justification documented.

    The policy explicitly classifies the GlucoWatch as experimental/investigational and not a covered item. The GlucoWatch measures interstitial glucose levels beyond three days and, per the policy, is excluded from coverage.

    For Medicare members, providers must follow applicable NCD/LCD guidance. This policy references Noridian LCD 33822 (Glucose Monitors) and the related Policy Article A52464; claims that do not meet these Medicare Part B contractor requirements or the referenced LCD may be excluded or denied.

    The policy identifies certain software and combination devices as not medically necessary. Specifically, additional software required to download CGM data to a computer is considered a convenience item and not medically necessary. Likewise, combination devices (for example, a blood glucose monitor integrated with a cellular telephone or other non‑diabetes‑specific device) are considered convenience items and are not medically necessary.

    Coding: HCPCS / CPT / ICD-10 and Device Durations

    Covered CPT/HCPCS codes (selected)mixedCovered
    95249Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training, and printout of recording.
    95250Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout recording.
    95251Analysis, interpretation and report; training, removal of sensor, and printout recording.
    A4238Supply allowance for adjunctive, non-implanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply.
    A4239Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply.
    S1031Continuous noninvasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor.
    Covered implantable and device codesmixedCovered
    0447TCreation of subcutaneous pocket with insertion of implantable interstitial glucose sensor including system activation and patient training.
    0448TRemoval of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation.
    E2102Adjunctive, non-implanted continuous glucose monitor or receiver.
    E2103Non-adjunctive, non-implanted continuous glucose monitor or receiver.
    CPT or HCPCS codes NOT coveredmixedNot Covered
    No codes listed
    Applicable ICD-10 diagnosis codes (Appendix 2)ICD-10Covered
    E08.29Diabetes mellitus due to underlying condition with other diabetic kidney complication
    E08.311-E08.319Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy / related retinopathy codes block
    E08.3211-E08.3219Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema
    E08.3291-E08.3299Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema
    E08.3311-E08.3319Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema
    E08.3391-E08.3399Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema
    E08.3411-E08.3419Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema
    E08.3491-E08.3499Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema
    E08.3511-E08.3519Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
    E08.3521-E08.3529Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula
    1–10 of 32
    1/4
    Referenced NCD/LCD and policy articlesmixed
    LCD 33822Noridian Local Coverage Determination - Glucose Monitors
    Policy Article A52464Noridian Glucose Monitor - Policy Article
    Sensor wear duration (per device) — examples
    Freestyle Libre 3 PlusSensor wear duration: 15 days
    Dexcom G6Sensor wear duration: 10 days
    Dexcom G7Sensor wear duration: 10 days
    Medtronic Guardian 4Sensor wear duration: 7 days
    Eversense (implantable)Sensor wear duration: 365 days
    Medicare MAC Jurisdictions (Noridian guidance)

    Provider Actions: Authorization, Documentation, and Billing Guidance

    Prior Authorization

    Prior authorization with required clinical documentation

    Prior authorization is required for CGM devices and related procedures. Include the following clinical documentation with the prior authorization request when available: physician progress notes for the past six months; documentation of completion of a comprehensive diabetes program and sufficient training regarding the specific device; recent laboratory reports including HbA1c; and blood glucose logs.

    • Physician progress notes (past 6 months)
    • Documentation of completion of a comprehensive diabetes program
    • Device-specific training documentation
    • Laboratory reports including HbA1c
    • Blood glucose logs
    Note

    Follow NCD/LCD; plan discretion for additional indications

    Follow any applicable Medicare NCDs and LCDs when billing Medicare Part B; the policy identifies Noridian LCD 33822 and Policy Article A52464 as relevant. The health plan may cover additional indications at its discretion.

    Background

    Continuous glucose monitoring (CGM) systems provide real‑time or intermittently scanned measurements of interstitial glucose to support diabetes management. CGM is used for short‑term diagnostic evaluations (typically 72 hours to 1 week) to identify hypoglycemia, hyperglycemia, postprandial excursions, and glucose variability, and for long‑term therapeutic management (duration >1 week) in people with diabetes—particularly those on intensive insulin regimens or with problematic hypoglycemia. CGM assists clinicians and patients by revealing glucose trends and patterns that inform treatment adjustments, training, and safety strategies.

    Definitions

    Definitions — rtCGM, isCGM, and implantable CGM
    rtCGM (real‑time CGM)Continuous real‑time interstitial glucose measurements transmitted to the user to support diabetes management; FDA‑approved real‑time CGM systems are listed in Appendix 1.
    isCGM (intermittently scanned CGM)Intermittently scanned systems that provide glucose readings when the sensor is scanned by the user rather than continuous automatic transmission.
    Implantable CGMSubcutaneously implanted sensor systems (e.g., Eversense) that provide long‑term interstitial glucose monitoring and require FDA approval; implantable devices have specific age and tolerance criteria for coverage.
    Applicable ICD-10 diagnosis codes (Appendix 2)
    Acceptable ICD-10 diagnosis codesAppendix 2 lists applicable diagnosis codes across diabetes categories (E08–E13) and pregnancy-related codes (O24 series) that are acceptable for CGM-related claims.
    Policy Summary
    PayerModa Health
    PolicyContinuous Glucose Monitoring (CGM)
    Policy CodePolicy N/A
    Change TypeOperational update: implantable CGM criteria added
    Effective DateJun 1, 2026
    Last ReviewMay 27, 2026
    Next Review DateMay 27, 2026
    Key ActionInclude clinical documentation (progress notes, device training, recent HbA1c, glucose logs) with prior authorization requests for CGM.
    SourceLink
    On This Page
    Coverage Criteria for Continuous Glucose Monitoring (CGM)Coding: HCPCS / CPT / ICD-10 and Device DurationsProvider Actions: Authorization, Documentation, and Billing GuidanceBackgroundDefinitions
    Noridian MAC Jurisdictions (Jurisdictions 5 and 8)Noridian Local Coverage Determination (LCD) 33822 applies
    Jurisdiction F (2 & 3) — StatesAK, WA, OR, ID, ND, SD, MT, WY, UT, AZ
    Contractor for Jurisdiction F (2 & 3)Noridian Healthcare Solutions, LLC
    • Comply with applicable NCD/LCD requirements (e.g., Noridian LCD 33822)
    • Health plan may cover additional indications at its discretion
    Step Therapy

    Step therapy not required

    No step therapy requirements are specified in this policy for CGM devices or related supplies.

    Documentation Required

    Claims must include applicable diagnosis and follow CMS guidance

    Providers should ensure claims include an applicable ICD‑10 diagnosis from Appendix 2 and follow CMS/NCD/LCD guidance when billing Medicare Part B.

    • Document an applicable ICD‑10 diagnosis from Appendix 2 on claims
    • Follow CMS/NCD/LCD guidance referenced in the policy when billing Medicare Part B
    Prior Authorization

    Prior authorization — required documentation checklist

    Prior authorization requests must include: physician progress notes for the past six months; documentation of completion of a comprehensive diabetes program and sufficient device training; recent HbA1c laboratory reports; and blood glucose logs.

    • Physician progress notes (past 6 months)
    • Completion of comprehensive diabetes program
    • Sufficient training regarding specific device
    • Laboratory reports including HbA1c
    • Blood glucose logs
    Billing Rule

    Diagnosis coding and CMS guidance for claims

    When submitting claims, document an applicable ICD‑10 diagnosis code from Appendix 2 and follow any applicable NCD/LCD guidance (e.g., Noridian LCD 33822) and CMS billing instructions for Medicare Part B.

    • Use an Appendix 2 ICD‑10 diagnosis code on claims
    • Adhere to NCD/LCD guidance and CMS billing rules for Medicare Part B
    Denial Risk

    Denial risk — insufficient clinical indication or excluded device

    Requests lacking documentation that the member meets one of the listed diagnostic or therapeutic criteria, or requests for excluded devices or convenience software, may be denied.

    • Denial risk if documentation does not show member meets diagnostic/therapeutic criteria (e.g., hypoglycemia unawareness, wide glucose fluctuations)
    • Denial risk for excluded items (e.g., GlucoWatch, software for data download, combination convenience devices)
    Denial Risk

    Denial risk — Medicare/NCD/LCD noncompliance

    Claims that do not comply with applicable NCD/LCD guidance or Medicare contractor requirements (for example Noridian LCD 33822 and related policy article) may be denied.

    • Noncompliance with NCD/LCD (e.g., Noridian LCD 33822) or Medicare contractor rules can result in claim denials
    Type categories included
    E08 (diabetes due to underlying condition), E09 (drug/chemical-induced), E10 (Type 1), E11 (Type 2), E13 (other specified), and O24 (pre-existing diabetes in pregnancy).
    Usage on claimsProviders should document an applicable ICD‑10 diagnosis from Appendix 2 on claims for CGM services and supplies.